| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Clinical Trials |
Departments of Biomathematics [K. R. H.], Clinical Investigation [M. C. A., M. N. R.], and Gastrointestinal Medical Oncology and Digestive Diseases [R. L., J. L. A.], The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030.
The clinical features and survival times of patients with unknown primary carcinoma (UPC) are heterogeneous. Therefore, the goals of this study were to apply a novel analytical method to UPC patients to: (a) identify novel prognostic factors; (b) explore the interactions between clinical variables and their impact on survival; and (c) illustrate explicitly how the covariates interact. The 1000 patients analyzed were referred to the University of Texas M. D. Anderson Cancer Center from January 1, 1987 through November 30, 1994. Clinical data from these patients were entered into a computerized database for storage, retrieval, and analysis. Multivariate analyses of survival were performed using recursive partitioning referred to as classification and regression tree (CART) analysis. The median survival for all 1000 consecutive UPC patients was 11 months. CART was performed with an initial split on liver involvement, and 10 terminal subgroups were formed. Median survival of the 10 subgroups ranged from 40 months (95% confidence interval, 22–66 months) for UPC patients with one or two metastatic organ sites, with nonadenocarcinoma histology, and without liver, bone, adrenal, or pleural metastases to 5 months (95% confidence interval, 4–7 months) in UPC patients with liver metastases, tumor histologies other than neuroendocrine carcinoma, age >61.5 years, and a small subgroup of patients with adrenal metastases. Two additional trees were also explored. These analyses demonstrated that important prognostic variables were consistently applied by the CART program and effectively segregated patients into groups with similar clinical features and survival. CART also identified previously unappreciated patient subsets and is a useful method for dissecting complex clinical situations and identifying homogeneous patient populations for future clinical trials.
This article has been cited by other articles:
|
|
 |
|
  A. Levy, C. Massard, M. Gross-Goupil, and K. Fizazi Carcinomas of an unknown primary site: a curable disease? Ann. Onc., September 1, 2008; 19(9): 1657 - 1658. [Full Text] [PDF]
|
|
|
|
 |
|
 C. K. Kuhl Current Status of Breast MR Imaging * Part 2. Clinical Applications Radiology, September 1, 2007; 244(3): 672 - 691. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Hainsworth, D. R. Spigel, C. Farley, D. S. Thompson, D. L. Shipley, and F. A. Greco Phase II Trial of Bevacizumab and Erlotinib in Carcinomas of Unknown Primary Site: The Minnie Pearl Cancer Research Network J. Clin. Oncol., May 1, 2007; 25(13): 1747 - 1752. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. A. Valera, B. A. Walter, N. Yokoyama, Y. Koyama, T. Iiai, H. Okamoto, and K. Hatakeyama Prognostic Groups in Colorectal Carcinoma Patients Based on Tumor Cell Proliferation and Classification and Regression Tree (CART) Survival Analysis Ann. Surg. Oncol., January 1, 2007; 14(1): 34 - 40. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P Conaghan, M A D'Agostino, P Ravaud, G Baron, M Le Bars, W Grassi, E Martin-Mola, R Wakefield, J-L Brasseur, A So, et al. EULAR report on the use of ultrasonography in painful knee osteoarthritis. Part 2: Exploring decision rules for clinical utility Ann Rheum Dis, December 1, 2005; 64(12): 1710 - 1714. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Nathan, J. H. Healey, D. Mellano, B. Hoang, I. Lewis, C. D. Morris, E. A. Athanasian, and P. J. Boland Survival in Patients Operated on for Pathologic Fracture: Implications for End-of-Life Orthopedic Care J. Clin. Oncol., September 1, 2005; 23(25): 6072 - 6082. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. A. Greco, G. I. Rodriguez, D. W. Shaffer, R. Hermann, S. Litchy, D. A. Yardley, H. A. Burris III, L. H. Morrissey, J. B. Erland, and J. D. Hainsworth Carcinoma of Unknown Primary Site: Sequential Treatment with Paclitaxel/Carboplatin/Etoposide and Gemcitabine/Irinotecan: A Minnie Pearl Cancer Research Network Phase II Trial Oncologist, November 1, 2004; 9(6): 644 - 652. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Koziol, J.-Y. Zhang, C. A. Casiano, X.-X. Peng, F.-D. Shi, A. C. Feng, E. K. L. Chan, and E. M. Tan Recursive Partitioning as an Approach to Selection of Immune Markers for Tumor Diagnosis Clin. Cancer Res., November 1, 2003; 9(14): 5120 - 5126. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Balana, J.-L. Manzano, I. Moreno, B. Cirauqui, A. Abad, A. Font, J.-L. Mate, and R. Rosell A phase II study of cisplatin, etoposide and gemcitabine in an unfavourable group of patients with carcinoma of unknown primary site Ann. Onc., September 1, 2003; 14(9): 1425 - 1429. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Culine, A. Kramar, M. Saghatchian, R. Bugat, T. Lesimple, A. Lortholary, Y. Merrouche, A. Laplanche, and K. Fizazi Development and Validation of a Prognostic Model to Predict the Length of Survival in Patients With Carcinomas of an Unknown Primary Site J. Clin. Oncol., December 15, 2002; 20(24): 4679 - 4683. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
